Print this page    •   Back to Web version of article

Table of Contents

February 1998

EDITORIAL

Better Safe Than Sorry

Does reducing viral load reduce the risk of transmitting HIV?
PAUL A. VOLBERDING, M.D.


THERAPEUTIC ADVANCES

The Next Generation of Antiretroviral Agents

Potent and promising new drugs will soon be available to combat HIV infection
HAROLD A. KESSLER, M.D.


NEWSLINE

NEWSLINE ... NEWSLINE ... NEWSLINE ...

Fomivirsen proves effective against CMV retinitis ... Patients are warned not to resume taking abacavir if they have an allergic reaction to it ... d4T plus 3TC, a therapeutic option in people who develop resistance to AZT ... "Protease paunch" and "buffalo hump": Combination therapy can lead to unusual fatty deposits ... Sustiva® now available to anyone with a CD4 count below 400 ... HAART therapy leads to resolution of MAC infection ...

Plus: what this means for you: HIV experts tell you, in clear, concise language, what impact these developments are likely to have on your day-to-day life.


PULL OUT AND SAVE

Clinical Trials You May Wish to Enroll In

A list of current clinical trials that involve various combinations of anti-HIV drugs, some of which cannot otherwise be obtained by people living with HIV infection


CONTINUING CARE

Better Treatment for CMV Retinitis

New drugs and new strategies can slow disease progression
MARK A. JACOBSON, M.D.




This article was provided by San Francisco General Hospital. It is a part of the publication AIDS Care. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art12686.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.